AR039367A1 - Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos - Google Patents

Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos

Info

Publication number: AR039367A1
Authority: AR; Argentina
Prior art keywords: lower alkyl; formula; compound; morpholinyl; cycloalkyl
Prior art date: 2001-11-19

Application number

ARP020104416A

Other languages

English (en)

Spanish (es)

Inventor

Alexander Flohr

Roland Jakob-Roetne

Roger David Norcross

Claus Riemer

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-19

Filing date

2002-11-18

Publication date

2005-02-16

2002-11-18 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2005-02-16 Publication of AR039367A1 publication Critical patent/AR039367A1/es

Links

150000001875 compounds Chemical class 0.000 title abstract 25
238000000034 method Methods 0.000 title abstract 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title abstract 2
UEIZUEWXLJOVLD-UHFFFAOYSA-N 3-(1-methylpyrrolidin-3-yl)pyridine Chemical compound C1N(C)CCC1C1=CC=CN=C1 UEIZUEWXLJOVLD-UHFFFAOYSA-N 0.000 title abstract 2
229960002715 nicotine Drugs 0.000 title abstract 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 36
125000003545 alkoxy group Chemical group 0.000 abstract 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 6
125000000753 cycloalkyl group Chemical group 0.000 abstract 6
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
125000002757 morpholinyl group Chemical group 0.000 abstract 5
-1 or is acetidinyl Chemical group 0.000 abstract 4
125000003386 piperidinyl group Chemical group 0.000 abstract 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 3
229910052794 bromium Chemical group 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
208000024827 Alzheimer disease Diseases 0.000 abstract 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
241000282326 Felis catus Species 0.000 abstract 2
208000018737 Parkinson disease Diseases 0.000 abstract 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
239000001961 anticonvulsive agent Substances 0.000 abstract 2
239000000460 chlorine Substances 0.000 abstract 2
229910052801 chlorine Inorganic materials 0.000 abstract 2
125000001309 chloro group Chemical group Cl* 0.000 abstract 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
230000004112 neuroprotection Effects 0.000 abstract 2
125000004043 oxo group Chemical group O=* 0.000 abstract 2
125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000011117 substance-related disease Diseases 0.000 abstract 2
102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
108050000203 Adenosine receptors Proteins 0.000 abstract 1
102000009346 Adenosine receptors Human genes 0.000 abstract 1
101150051188 Adora2a gene Proteins 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
SRPCCBAOIRMMRV-UHFFFAOYSA-N C1=CC=C2SC=NC2=C1.CN1CCCC1C1=CC=CN=C1 Chemical compound C1=CC=C2SC=NC2=C1.CN1CCCC1C1=CC=CN=C1 SRPCCBAOIRMMRV-UHFFFAOYSA-N 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
208000020401 Depressive disease Diseases 0.000 abstract 1
208000010496 Heart Arrest Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
206010021143 Hypoxia Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
229960005305 adenosine Drugs 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
230000003556 anti-epileptic effect Effects 0.000 abstract 1
229940125681 anticonvulsant agent Drugs 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000000164 antipsychotic agent Substances 0.000 abstract 1
229940005529 antipsychotics Drugs 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 abstract 1
125000001246 bromo group Chemical group Br* 0.000 abstract 1
229930003827 cannabinoid Natural products 0.000 abstract 1
239000003557 cannabinoid Substances 0.000 abstract 1
229940065144 cannabinoids Drugs 0.000 abstract 1
229940045200 cardioprotective agent Drugs 0.000 abstract 1
239000012659 cardioprotective agent Substances 0.000 abstract 1
239000003054 catalyst Substances 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
229960003920 cocaine Drugs 0.000 abstract 1
208000029078 coronary artery disease Diseases 0.000 abstract 1
125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
230000006735 deficit Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
206010013663 drug dependence Diseases 0.000 abstract 1
229960004756 ethanol Drugs 0.000 abstract 1
230000007954 hypoxia Effects 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
229940035363 muscle relaxants Drugs 0.000 abstract 1
239000003158 myorelaxant agent Substances 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
229940005483 opioid analgesics Drugs 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
230000036407 pain Effects 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000004193 piperazinyl group Chemical group 0.000 abstract 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
230000000241 respiratory effect Effects 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
229940125723 sedative agent Drugs 0.000 abstract 1
239000000932 sedative agent Substances 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1
231100000736 substance abuse Toxicity 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ARP020104416A 2001-11-19 2002-11-18 Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos AR039367A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01127312		2001-11-19

Publications (1)

Publication Number	Publication Date
AR039367A1 true AR039367A1 (es)	2005-02-16

Family

ID=8179263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP020104416A AR039367A1 (es)	2001-11-19	2002-11-18	Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos

Country Status (38)

Country	Link
US (1)	US6620811B2 (fr)
EP (1)	EP1448198B1 (fr)
JP (1)	JP4226474B2 (fr)
KR (1)	KR100577110B1 (fr)
CN (1)	CN100546580C (fr)
AR (1)	AR039367A1 (fr)
AT (1)	ATE376831T1 (fr)
AU (1)	AU2002351955B2 (fr)
BR (1)	BR0214245A (fr)
CA (1)	CA2467552C (fr)
DE (1)	DE60223278T2 (fr)
DK (1)	DK1448198T3 (fr)
EA (1)	EA007502B1 (fr)
EC (1)	ECSP045109A (fr)
ES (1)	ES2294187T3 (fr)
GT (1)	GT200200232A (fr)
HR (1)	HRP20040396A2 (fr)
HU (1)	HUP0402161A3 (fr)
IL (2)	IL161623A0 (fr)
JO (1)	JO2290B1 (fr)
MA (1)	MA27083A1 (fr)
MX (1)	MXPA04004684A (fr)
MY (1)	MY126176A (fr)
NO (1)	NO20042576L (fr)
NZ (1)	NZ532802A (fr)
PA (1)	PA8558001A1 (fr)
PE (1)	PE20030713A1 (fr)
PL (1)	PL369517A1 (fr)
PT (1)	PT1448198E (fr)
RS (1)	RS39904A (fr)
RU (1)	RU2294933C2 (fr)
SI (1)	SI1448198T1 (fr)
TN (1)	TNSN04087A1 (fr)
TW (1)	TW200407134A (fr)
UA (1)	UA77462C2 (fr)
UY (1)	UY27542A1 (fr)
WO (1)	WO2003043636A1 (fr)
ZA (1)	ZA200403817B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ522928A (en) *	2000-06-21	2005-05-27	F	Benzothiazole derivatives
ES2357808T3 (es) *	2001-06-07	2011-04-29	Christine Dr. Sang	Tratamiento del dolor neuropático con antagonistas del receptor de n-metil-d-aspartato (nmda).
US6734179B2 (en) *	2001-12-12	2004-05-11	Hoffmann-La Roche Inc.	Benzothiazoles
US20050119251A1 (en) *	2001-12-21	2005-06-02	Jian-Min Fu	Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en)	2001-12-21	2008-06-24	Xenon Pharmaceuticals Inc.	Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US6872833B2 (en)	2003-04-14	2005-03-29	Hoffmann-La Roche Inc.	Adenosine receptor ligands
EP1653968A4 (fr) *	2003-07-23	2006-09-06	Synta Pharmaceuticals Corp	Procede de modulation de canaux d'ions calcium actives par la liberation d'ions calcium
EP3042895A1 (fr)	2003-07-30	2016-07-13	Xenon Pharmaceuticals Inc.	Dérivés de la pipérazine et leur utilisation en tant qu'agents thérapeutiques
AU2004274154A1 (en)	2003-09-19	2005-03-31	F. Hoffmann-La Roche Ag	Thiazolopyridine derivatives as adenosine receptor ligands
CA2543707A1 (fr)	2003-10-31	2005-05-19	Takeda Pharmaceutical Company Limited	Composes heterocycliques accoles contenant de l'azote
JP4638355B2 (ja)	2003-12-26	2011-02-23	協和発酵キリン株式会社	チアゾール誘導体
BRPI0418939A (pt) *	2004-07-06	2008-04-08	Xenon Pharmaceuticals Inc	derivados de nicotinamida e sua utilização como agentes terapêuticos
EP1773827B1 (fr) *	2004-07-22	2010-02-17	F.Hoffmann-La Roche Ag	Derives de benzothiazole
KR100823799B1 (ko) *	2004-07-22	2008-04-21	에프. 호프만-라 로슈 아게	벤조티아졸 유도체
KR100818028B1 (ko)	2004-07-22	2008-03-31	에프. 호프만-라 로슈 아게	치환된 벤조티아졸
JP4958786B2 (ja) *	2004-09-20	2012-06-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	複素環誘導体および治療薬としてのそれらの使用
US7547698B2 (en) *	2004-09-20	2009-06-16	Xenon Pharmaceuticals Inc.	Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)
EP2269610A3 (fr)	2004-09-20	2011-03-09	Xenon Pharmaceuticals Inc.	Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
US20080167321A1 (en) *	2004-09-20	2008-07-10	Xenon Pharmaceuticals Inc.	Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
EP2289510A1 (fr)	2004-09-20	2011-03-02	Xenon Pharmaceuticals Inc.	Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
EP1799667B1 (fr) *	2004-09-20	2013-03-20	Xenon Pharmaceuticals Inc.	Derives heterocycliques et leur utilisation comme agents therapeutiques
MX2007003327A (es) *	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
MX2007003332A (es) *	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
MX2007003319A (es) *	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como agentes terapeuticos.
CA2586931C (fr) *	2004-11-05	2013-08-06	Paul Spurr	Procede pour preparer des derives d'acide isonicotinique
MX2007011234A (es) *	2005-03-14	2007-11-12	Transtech Pharma Inc	Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
BRPI0611187A2 (pt) *	2005-06-03	2010-08-24	Xenon Pharmaceuticals Inc	derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
CA2669311C (fr) *	2006-11-13	2011-09-20	Pfizer Products Inc.	Derives diaryle, dipyridinyle et aryl-pyridinyle et leurs utilisations
EP2424533A4 (fr)	2009-04-27	2012-10-17	High Point Pharmaceuticals Llc	Dérivés d'isoquinoline substitués, compositions pharmaceutiques et leurs méthodes d'utilisation en tant qu'inhibiteurs de -sécrétase
TWI548411B (zh)	2009-04-28	2016-09-11	Kyowa Hakko Kirin Co Ltd	Exercise disorder treatment
UA110097C2 (uk)	2009-09-02	2015-11-25		Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx)	2009-09-02	2017-01-25		Терапевтичний агент для лікування тривожних розладів
EP2549874A4 (fr) *	2010-03-23	2013-10-02	High Point Pharmaceuticals Llc	Dérivés d'imidazole[1,2-b]pyridazine substitués, compositions pharmaceutiques et procédés d'utilisation en tant qu'inhibiteurs de bêta-sécrétase
JP5248585B2 (ja) *	2010-12-15	2013-07-31	ゼノン・ファーマシューティカルズ・インコーポレイテッド	治療薬としてのニコチンアミド誘導体およびそれらの使用
DE102011005232A1 (de)	2011-03-08	2012-09-13	AristoCon GmbH & Co. KG	Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
BR112015007083A2 (pt)	2012-10-02	2017-07-04	Epitherapeutics Aps	inibidores de histona demetilases
WO2020103930A1 (fr) *	2018-11-22	2020-05-28	上海科技大学	Composé thiazolo cyclique, son procédé de préparation, intermédiaire correspondant et utilisation associée
DE102019110904B4 (de) *	2019-04-26	2022-01-20	Helmholtz-Zentrum Dresden - Rossendorf E. V.	N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0113219B1 (fr)	1982-12-21	1987-11-19	Johnsen & Jorgensen (Plastics) Limited	Récipient distributeur
FI91859C (fi) *	1987-06-17	1994-08-25	Eisai Co Ltd	Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) *	1988-05-24	1989-12-15	Pfizer	Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
NZ522928A (en)	2000-06-21	2005-05-27	F	Benzothiazole derivatives

2002
- 2002-11-05 US US10/288,100 patent/US6620811B2/en not_active Expired - Lifetime
- 2002-11-11 KR KR1020047007638A patent/KR100577110B1/ko not_active Expired - Fee Related
- 2002-11-11 NZ NZ532802A patent/NZ532802A/en unknown
- 2002-11-11 WO PCT/EP2002/012562 patent/WO2003043636A1/fr not_active Ceased
- 2002-11-11 SI SI200230637T patent/SI1448198T1/sl unknown
- 2002-11-11 UA UA20040604552A patent/UA77462C2/uk unknown
- 2002-11-11 CA CA2467552A patent/CA2467552C/fr not_active Expired - Fee Related
- 2002-11-11 RU RU2004118425/04A patent/RU2294933C2/ru not_active IP Right Cessation
- 2002-11-11 MX MXPA04004684A patent/MXPA04004684A/es active IP Right Grant
- 2002-11-11 CN CNB028228391A patent/CN100546580C/zh not_active Expired - Fee Related
- 2002-11-11 HU HU0402161A patent/HUP0402161A3/hu not_active Application Discontinuation
- 2002-11-11 DK DK02787632T patent/DK1448198T3/da active
- 2002-11-11 EA EA200400598A patent/EA007502B1/ru not_active IP Right Cessation
- 2002-11-11 AT AT02787632T patent/ATE376831T1/de active
- 2002-11-11 BR BR0214245-7A patent/BR0214245A/pt not_active IP Right Cessation
- 2002-11-11 ES ES02787632T patent/ES2294187T3/es not_active Expired - Lifetime
- 2002-11-11 IL IL16162302A patent/IL161623A0/xx unknown
- 2002-11-11 PT PT02787632T patent/PT1448198E/pt unknown
- 2002-11-11 EP EP02787632A patent/EP1448198B1/fr not_active Expired - Lifetime
- 2002-11-11 AU AU2002351955A patent/AU2002351955B2/en not_active Ceased
- 2002-11-11 PL PL02369517A patent/PL369517A1/xx not_active Application Discontinuation
- 2002-11-11 JP JP2003545317A patent/JP4226474B2/ja not_active Expired - Fee Related
- 2002-11-11 RS YU39904A patent/RS39904A/sr unknown
- 2002-11-11 HR HR20040396A patent/HRP20040396A2/hr not_active Application Discontinuation
- 2002-11-11 DE DE60223278T patent/DE60223278T2/de not_active Expired - Lifetime
- 2002-11-14 TW TW091133371A patent/TW200407134A/zh unknown
- 2002-11-14 PA PA20028558001A patent/PA8558001A1/es unknown
- 2002-11-15 PE PE2002001104A patent/PE20030713A1/es not_active Application Discontinuation
- 2002-11-18 UY UY27542A patent/UY27542A1/es not_active Application Discontinuation
- 2002-11-18 GT GT200200232A patent/GT200200232A/es unknown
- 2002-11-18 AR ARP020104416A patent/AR039367A1/es unknown
- 2002-11-18 JO JO2002114A patent/JO2290B1/en active
- 2002-11-18 MY MYPI20024303A patent/MY126176A/en unknown
2004
- 2004-04-26 IL IL161623A patent/IL161623A/en not_active IP Right Cessation
- 2004-05-17 EC EC2004005109A patent/ECSP045109A/es unknown
- 2004-05-18 TN TNP2004000087A patent/TNSN04087A1/en unknown
- 2004-05-18 MA MA27681A patent/MA27083A1/fr unknown
- 2004-05-18 ZA ZA200403817A patent/ZA200403817B/en unknown
- 2004-06-18 NO NO20042576A patent/NO20042576L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR100577110B1 (ko)	2006-05-10
IL161623A0 (en)	2004-09-27
RU2294933C2 (ru)	2007-03-10
UA77462C2 (en)	2006-12-15
PT1448198E (pt)	2007-12-11
JO2290B1 (en)	2005-09-12
ZA200403817B (en)	2005-05-23
EP1448198B1 (fr)	2007-10-31
CN100546580C (zh)	2009-10-07
US6620811B2 (en)	2003-09-16
ES2294187T3 (es)	2008-04-01
HUP0402161A3 (en)	2010-06-28
DE60223278D1 (de)	2007-12-13
ATE376831T1 (de)	2007-11-15
JP4226474B2 (ja)	2009-02-18
HUP0402161A2 (hu)	2005-02-28
CN1617722A (zh)	2005-05-18
TW200407134A (en)	2004-05-16
MY126176A (en)	2006-09-29
PL369517A1 (en)	2005-04-18
PE20030713A1 (es)	2003-08-23
EA007502B1 (ru)	2006-10-27
UY27542A1 (es)	2003-05-30
US20030134854A1 (en)	2003-07-17
PA8558001A1 (es)	2003-07-28
SI1448198T1 (sl)	2008-02-29
TNSN04087A1 (en)	2006-06-01
CA2467552A1 (fr)	2003-05-30
BR0214245A (pt)	2004-12-14
KR20050044535A (ko)	2005-05-12
ECSP045109A (es)	2004-06-28
HRP20040396A2 (en)	2005-04-30
DE60223278T2 (de)	2008-08-14
GT200200232A (es)	2003-06-17
AU2002351955A1 (en)	2003-06-10
AU2002351955B2 (en)	2007-03-15
NO20042576L (no)	2004-06-18
MXPA04004684A (es)	2004-08-12
CA2467552C (fr)	2011-05-24
WO2003043636A1 (fr)	2003-05-30
JP2005522413A (ja)	2005-07-28
NZ532802A (en)	2005-07-29
RU2004118425A (ru)	2006-01-10
EP1448198A1 (fr)	2004-08-25
EA200400598A1 (ru)	2005-02-24
MA27083A1 (fr)	2004-12-20
RS39904A (sr)	2006-10-27
IL161623A (en)	2010-11-30
DK1448198T3 (da)	2008-01-07

Legal Events

Date	Code	Title	Description
2009-06-22	FB	Suspension of granting procedure

Publication	Publication Date	Title
EP2274307B1 (fr)	2015-07-29	Composés hétérocycliques pontés et leurs procédés d'utilisation
DE69724108T2 (de)	2004-06-09	Isochinolinderivate und arzneimittel
DE69031649T2 (de)	1998-02-26	Oxoindolderivate
BRPI0414266A (pt)	2006-11-07	derivados de tiazolopiridina como ligandos receptores da adenosina
HUP0402161A2 (hu)	2005-02-28	Nikotin- vagy izonikotin-benzotiazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2898836T3 (es)	2022-03-09	Compuestos de amino-naft[1,2-d]imidazol-5-ona 2-sustituida o sales farmacéuticamente aceptables de los mismos
KR20140113918A (ko)	2014-09-25	루게릭병의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
HUP0302526A2 (hu)	2003-11-28	Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ES2705400T3 (es)	2019-03-25	Sulfonas heterocíclicas como moduladores de ROR gamma
BRPI0710232B1 (pt)	2020-08-11	Composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina
JP2023512821A5 (fr)	2024-02-13
DE69034162D1 (de)	2004-10-14	N-substituierte Cycloalkyl- und Polycycloalkyl-alpha-substituierte Trp-Phe- und Phenethylaminderivate
EA025276B1 (ru)	2016-12-30	(2S,3S)-3-((2-(5-ФТОР-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-ИЛ)-5-ФТОРПИРИМИДИН-4-ИЛ)АМИНО)БИЦИКЛО[2,2,2]ОКТАН-2-КАРБОНОВАЯ КИСЛОТА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ЕЁ, И СПОСОБЫ ПРИМЕНЕНИЯ УКАЗАННОГО СОЕДИНЕНИЯ
US9688675B2 (en)	2017-06-27	1,7-naphthyridine derivatives
CN113801073A (zh)	2021-12-17	14-氯-β-榄香烯一氧化氮供体型衍生物及其制备和应用
JP2020520925A (ja)	2020-07-16	化合物、組成物および方法
EP2590936B1 (fr)	2018-12-12	Composé de phénylcarbamate et relaxant musculaire le contenant
WO2014086098A1 (fr)	2014-06-12	Composé cyclohexane amine et son application pour des médicaments anti-schizophrénie
JP6229056B2 (ja)	2017-11-08	神経変性疾患の処置用の神経新生薬としてのピリド［４，３−ｂ］ピラジン−２−カルボキサミド
RU2007101052A (ru)	2008-08-27	Производные бензотиазола
AR037457A1 (es)	2004-11-10	Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen
TWI601712B (zh)	2017-10-11	作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物
JP4408292B2 (ja)	2010-02-03	ベンゾチアゾール誘導体、およびアデノシンａ２ａレセプターに関連する疾患の処置におけるその使用
AR037792A1 (es)	2004-12-01	Compuestos derivados de benzotiazol, su uso, un procedimiento para su obtencion y medicamentos que los contienen
RU2007101049A (ru)	2008-08-27	Замещенные бензотиазолы